| In millions, except per share items | Jun-30-23 | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Bioprocessing (iBio CDMO) | | | 2.4 | | | | | |
| Ibio Inc | | | | 1.5 | 2.0 | | | |
| iBio CDMO | | | | 0.1 | | 0.0 | 0.1 | 0.1 |
| Other | | | | | | 0.0 | 0.3 | 0.9 |
| Total revenues | 0.0 | 1.9 | 2.4 | 1.6 | 0.0 | 0.0 | 0.4 | 0.9 |
| Revenue growth [+] | -100.0% | -20.5% | 44.7% | 4327.0% | -15.9% | -88.8% | -58.4% | -48.8% |
| Ibio Inc | | | | -23.4% | | | | |
| iBio CDMO | | | | | | -69.9% | 123.6% | |
| Cost of goods sold | 0.0 | 0.0 | 1.5 | 0.0 | -2.0 | -0.4 | 0.0 | 0.0 |
| Gross profit | 0.0 | 1.9 | 0.9 | 1.6 | 2.0 | 0.4 | 0.4 | 0.9 |
| Gross margin | | 100.0% | 38.3% | 100.0% | 5454.1% | 1009.1% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 19.0 | 21.8 | 22.0 | 12.4 | 12.3 | 10.7 | 10.6 | 7.7 |
| General and administrative | 19.0 | 21.8 | 22.0 | 12.4 | 12.3 | 10.7 | 10.6 | 7.7 |
| Research and development | 10.3 | 9.8 | 10.0 | 3.2 | 5.5 | 4.0 | 4.1 | 3.2 |
| Other operating expenses | | | -10.2 | | | | | |
| EBITDA [+] | -28.5 | -27.0 | -20.1 | -13.4 | -14.0 | -12.5 | -12.6 | -9.0 |
| EBITDA growth | 5.6% | 34.1% | 50.1% | -4.4% | 12.2% | -0.6% | 40.7% | 42.0% |
| EBITDA margin | | -1434.2% | -849.8% | -819.5% | -37943.2% | -28450.0% | -3197.5% | -944.4% |
| Depreciation | 0.7 | 2.3 | 0.5 | 0.3 | 1.4 | 1.4 | 1.3 | 0.6 |
| EBITA | -29.2 | -29.3 | -20.6 | -13.7 | -15.5 | -13.9 | -13.9 | -9.5 |
| EBITA margin | | -1555.0% | -869.7% | -836.7% | -41800.0% | -31559.1% | -3534.0% | -1005.3% |
| Amortization of intangibles | 0.1 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 |
| EBIT [+] | -29.3 | -29.7 | -20.9 | -14.0 | -15.8 | -14.2 | -14.3 | -9.9 |
| EBIT growth | -1.2% | 42.0% | 49.3% | -11.3% | 11.0% | -0.3% | 44.3% | 48.4% |
| EBIT margin | | -1576.3% | -881.9% | -854.9% | -42670.3% | -32334.1% | -3622.8% | -1043.6% |
| Non-recurring items | | | 10.2 | | | | | |
| Interest expense, net [+] | -0.1 | -0.2 | 2.3 | 2.5 | 1.8 | 1.9 | 1.9 | 0.8 |
| Interest expense | 0.1 | | 2.5 | 2.5 | 1.9 | 1.9 | 1.9 | 0.8 |
| Interest income | 0.2 | 0.2 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | -0.1 | 0.0 | 10.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Royalty income | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -29.3 | -29.5 | -23.2 | -16.4 | -17.6 | -16.1 | -16.1 | -10.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Minority interest | | | 0.0 | 0.0 | 0.0 | 0.0 | -1.6 | -0.9 |
| Earnings from continuing ops | -29.3 | -29.5 | -23.5 | -38.3 | -17.9 | -16.4 | -14.6 | -9.8 |
| Earnings from discontinued ops | -35.7 | -20.8 | | | | | | |
| Net income | -65.0 | -50.3 | -23.5 | -38.3 | -17.9 | -16.4 | -14.6 | -9.8 |
| Net margin | | -2670.1% | -989.8% | -2335.8% | -48251.4% | -37193.2% | -3711.2% | -1030.0% |
| |
| Basic EPS [+] | ($2.39) | ($3.38) | ($3.00) | ($0.61) | ($0.94) | ($1.54) | ($1.64) | ($0.12) |
| Growth | -29.3% | 12.8% | 392.2% | -35.4% | -38.7% | -6.2% | 1260.8% | 30.1% |
| Diluted EPS [+] | ($2.39) | ($3.38) | ($3.00) | ($0.61) | ($0.94) | ($1.54) | ($1.64) | ($0.12) |
| Growth | -29.3% | 12.8% | 392.2% | -35.4% | -38.7% | -6.2% | 1260.8% | 30.1% |
| |
| Shares outstanding (basic) [+] | 12.2 | 8.7 | 7.8 | 62.8 | 18.9 | 10.6 | 8.9 | 81.0 |
| Growth | 40.4% | 11.5% | -87.5% | 231.8% | 78.0% | 19.3% | -89.0% | 13.3% |
| Shares outstanding (diluted) [+] | 12.2 | 8.7 | 7.8 | 62.8 | 18.9 | 10.6 | 8.9 | 81.0 |
| Growth | 40.4% | 11.5% | -87.5% | 231.8% | 78.0% | 19.3% | -89.0% | 13.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |